golf, you say.. "There has certainly been enough published on this."

Here is another one. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7438995/

It states the following:

"Apabetalone 

An international consortium of scientists has identified 50 proteins as putative drug targets against COVID-19. Amongst these targets, bromodomain (BRD) 2/4 would be relevant during interaction with the (E) envelope proteins of SARS-CoV-2 and viral reproduction.94 By mimicking the histone structure, the (E) envelope proteins might potentially disrupt BRD-histone complexes. BRD proteins are epigenetic players that bind acetylated groups on histone proteins to aid in the recruitment of transcriptional machinery at promoter genes. Apabetalone can directly inhibit BET2/4 protein–SARS-CoV-2 interaction and may downregulate the expression of ACE2 receptors, which are exploited by the surface S glycoprotein to enter into human cells.101 Currently, apabetalone is not approved by FDA, but has already shown clinical safety as demonstrated during the Phase 3 trial (BETonMACE) focusing on secondary prevention of cardiovascular dysfunction in diabetics.102 Overall, this evidence suggests that apabetalone may potentially reduce viral infection and replication. In this way, Resverlogix Corporation (https://bit.ly/2CBaEKB) invites collaborators for further research on apabetalone as a putative therapeutic strategy for COVID-19."

Just wondering that since Apabetalone is not yet FDA approved, (as noted) it's keeping it back from being paid attention to by collaborators for further research, assuming, of course, that this has not happened thus far. 

Koo 

.